FDMT Q2 2022 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$162,000-98.9% YoY

Gross Profit

-$20M-12506.2% margin

Operating Income

-$28M-17546.9% margin

Net Income

-$28M-17337.0% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

-86.7%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$303M

Total Liabilities

$30M

Stockholders' Equity

$273M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$162,000	$15M	-98.9%
Gross Profit	-$20M	-$643,000	-3050.9%
Operating Income	-$28M	-$8M	-274.2%
Net Income	-$28M	-$8M	-270.1%

Geographic Segments

NETHERLANDS

$160,00099%

UNITED STATES

$2,0001%